Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Table 3 The specific clinical and laboratory manifestations at different follow-up visits in each patient

Clinical features	Case 1 (weeks)					Case 2 (weeks)					Case 3 (weeks)					Case 4 (weeks)					Case 5 (weeks)					Case 6 (weeks)
Clinical features	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24
Fever	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-
Rash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
Lymphadenopathy	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-
Myalgia	+	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-
Arthritis	+	-	-	-	-	+	+	-	-	-	+	-	-	-	-	-	-	-	-	-	+	+	+	-	-	+	-	-	-	-
WBC > 15,000/mm³	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	+	+	-	-	-	-
CRP > 10 mg/L	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	+	-	-	+	+	-	-	-	-
ESR > 20 mm/h	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-	-	-	-	-	-
Ferritin > 330 ng/mL	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-

Clinical features	Case 7 (weeks)					Case 8 (weeks)					Case 9 (weeks)					Case 10 (weeks)					Case 11 (weeks)
Clinical features	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24	0	4	8	12	24
Fever	+	-	-	-	-	+	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-	-	-	-	-
Rash	+	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lymphadenopathy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Myalgia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arthritis	-	-	-	-	-	+	-	-	-	-	+	-	+	+	+	+	+	+	+	+	+	+	+	+	-
WBC > 15,000/mm³	+	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
CRP > 10 mg/L	+	-	-	-	-	+	-	-	-	-	+	+	+	+	+	+	-	-	-	+	+	-	-	-	-
ESR > 20 mm/h	+	-	-	-	-	+	-	-	-	-	+	-	+	+	+	+	-	+	+	+	+	-	-	-	-
Ferritin > 330 ng/mL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-

WBC White blood cell, CRP C-reactive protein, ESR Erythrocyte sedimentation rate

ISSN: 1546-0096